CytomX Therapeutics (NASDAQ: CTMX) saw its stock price plummet 6.92% in pre-market trading following the release of its disappointing third-quarter 2025 financial results. The biotech company's earnings and revenue figures fell significantly short of analyst expectations, triggering concern among investors.

The company reported a quarterly loss of $0.09 per share, missing the analyst consensus estimate of $0.05 by a wide margin. This represents a substantial decline from the $0.07 per share earnings reported in the same period last year. Revenue for the quarter came in at $5.96 million, falling well below the analyst estimate of $11.63 million and marking an 82.2% decrease compared to the $33.43 million reported in the previous year's quarter.

Despite the disappointing results, CytomX Therapeutics maintains a solid cash position, reporting $143.6 million in cash, cash equivalents, and investments at the end of the third quarter. The company expects this to provide a runway through the second quarter of 2027. CytomX attributes the revenue decline to the completion of Bristol Myers Squibb collaboration obligations and reduced Moderna activities. Looking ahead, the company plans to provide a CX-2051 Phase 1 data update in Q1 2026 and start a CX-2051 Phase 1b CRC study with bevacizumab in the same quarter, which could potentially impact future performance.